Lantibiotics are ribosomally synthesized and posttranslationally modified antimicrobial compounds containing lanthionine and methyl-lanthionine residues. Nisin, one of the most extensively studied and used lantibiotics, has been shown to display very potent activity against Gram-positive bacteria, and stable resistance is rarely observed. By binding to lipid II and forming pores in the membrane, nisin can cause the efflux of cellular constituents and inhibit cell wall biosynthesis. However, the activity of nisin against Gram-negative bacteria is much lower than that against Gram-positive bacteria, mainly because lipid II is located at the inner membrane, and the rather impermeable outer membrane in Gram-negative bacteria prevents nisin from reaching lipid II. Thus, if the outer membrane-traversing efficiency of nisin could be increased, the activity against Gram-negative bacteria could, in principle, be enhanced. In this work, several relatively short peptides with activity against Gram-negative bacteria were selected from literature data to be fused as tails to the C terminus of either full or truncated nisin species. Among these, we found that one of three tails (tail 2 [T2; DKYLPRPRPV], T6 [NGVQPKY], and T8 [KIAKVALKAL]) attached to a part of nisin displayed improved activity against Gram-negative microorganisms. Next, we rationally designed and reengineered the most promising fusion peptides. Several mutants whose activity significantly outperformed that of nisin against Gram-negative pathogens were obtained. The activity of the tail 16 mutant 2 (T16m2) construct against several important Gram-negative pathogens (i.e., Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter aerogenes) was increased 4-to 12-fold compared to that of nisin. This study indicates that the rational design of nisin can selectively and significantly improve its outer membrane-permeating capacity as well as its activity against Gram-negative pathogens.
Introduction
Nisin (Figure 1 ), produced by Lactococcus lactis, is the oldest known (since 1928) and most extensively studied lantibiotic [1, 2] . It is a potent lanthionine-containing antimicrobial peptide that is ribosomally synthesized and post-translationally modified. Unmodified prenisin contains 57 amino acids of which the first 23 amino acids correspond to the leader peptide and the last 34 residues compose the core peptide [2] . The leader peptide is crucial for unmodified prenisin to be recognized by the modification and transport proteins [2] [3] [4] . The precursor is processed by the modification machinery. Firstly, the serine and threonine residues are dehydrated to become dehydroalanines (Dha) or dehydrobutyrines (Dhb), respectively, by the NisB dehydratase [2, 3] . Dehydrated residues can then be coupled to a cysteine by the cyclization enzyme NisC [5] . Subsequently, the modified peptide is transported out of the cell by the transporter NisT [2, 4] . At this time, the fully modified nisin prepeptide is still inactive because of the presence of the leader peptide. Only after the leader sequence is cleaved off by the protease NisP, nisin becomes active and can induce the two-component system NisRK [6, 7] . It has been clearly demonstrated that NisB, NisC, and NisT have a relaxed substrate specificity and highly diverse peptides fused to the nisin leader can be efficiently modified [2, 3, 5, 8, 9] .
Nisin has been used in food industry as a natural preservative for decades, thanks to its high activity against bacteria and low toxicity for humans [2, 10] . It is highly effective against Gram-positive bacteria with minimal inhibitory concentrations (MICs) at nanomolar concentrations [1, 2, 5] . There are two different mechanisms of nisin to kill bacteria: pore formation in the membrane and inhibition of cellwall biosynthesis by binding to lipid II [1, 11, 12] . After nisin reaches the bacterial plasma membrane, a pyrophosphate cage is formed via hydrogen bonds, which involves the first two rings of nisin and the pyrophosphate moiety of lipid II. The pyrophosphate is responsible for the low resistance of bacteria to nisin, since the pyrophosphate is essential and not prone to mutation and also facilitates the transmembrane orientation of nisin [1, 12] .
Nevertheless, it is difficult for nisin to penetrate the outer-membrane barrier of Gram-negative bacteria and thus it cannot reach its target lipid II in the inner membrane. This leads to relatively low activity of nisin against Gram-negative bacteria. Conversely, nisin actually tends to bind to the usually anionic surface of the outer-membrane and stabilizes it via electrostatic interactions [13] . Notably, nisin can inhibit the growth of Gram-negative bacteria more efficiently, when chelating agents (EDTA, citrate monohydrate, or trisodium orthophosphate) are used to destabilize the outer membrane [14, 15] . Thus, the main bottleneck for nisin to be active against Gram-negative bacteria appears to be its ability passing the outer-membrane.
The outer-membrane of Gram-negative bacteria constitutes an efficient protective barrier to prevent various antimicrobials from reaching the cellular membrane and exert their function. To address this issue, we have designed hybrid compounds based on the antimicrobial nisin and other antimicrobial peptides that combine different functionalities. Thus, we develop ways to enable antimicrobials to pass the outer membrane of Gram-negative organisms, while retaining as much as possible their antimicrobial function at the cytoplasmic membrane. Some mutants have been made previously [16] . In those mutants, full nisin or parts of nisin were fused to different tails with reported activity against Gram negative bacteria to create antimicrobial peptides targeted against Gram-negative pathogens [16] . These tails are mainly cationic peptides secreted by amphibians, insects, or immune cells, including proline-rich antimicrobial peptides (Table 1) . Their mechanisms of action are unclear in many cases, but to reach their targets, it is clear that they must interact with and cross the outer-membrane. Because peptide GNT 16 was reported by our group to have 2-fold improved activity against E. coli [16] , in this work the tail 16 (T16) sequence "PRPPHPRL" was also used for further engineering. In addition, we chose several Gram-negative pathogens from the Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species (ESKAPE) group of pathogens as well as Escherichia coli as indicator strains for MIC tests. In the course of the experiments, we did further rational design of the peptides on both the tail and the nisin parts. We found that several hybrid peptides had considerably higher activity than nisin against different multidrug-resistant (MDR) Gram-negative pathogens. The tail 16 (T16) mutant 2 (T16m2) construct was proven to display the onine. Prenisin (gray) contains a leader peptide and a core peptide (1-34 amino acids). The six histidine residues are located at the N-terminus and labeled in yellow. The ABCDE rings are marked. The structures of fusion peptides are indicated, with the linker labeled in purple (serine and glycine) while Gram-negative tails are labeled with green. Group 1 contains full nisin and anti-Gram negative tails. Group 2 contains ABCDE rings of nisin, hinge region (serine and glycine) and anti-Gram-negative tails best activity and it was found to be 4~12 times more efficient than nisin, depending on the target organism used. This study reports on the bioengineering and rational design of nisin and tails with activity against Gram-negative bacteria to substantially increase the activity of nisin against MDR Gram-negative pathogens.
Materials and methods

Bacterial strains and growth conditions
The bacteria used in this study are listed in Table 2 . L. lactis strains were cultured in M17 broth supplemented with 0.5 % (w/v) glucose (GM17) or GM17 agar for genetic manipulation or in minimal expression medium (MEM) [3] for protein expression at 30 °C. Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacter aerogenes were grown in shaken Luria-Bertani (LB) broth or on LB agar at 37 °C. The bacteria with LMG number were obtained from the Belgian Co-ordinated Collections of Micro-organisms (BCCM).
Chloramphenicol and/or erythromycin were used at 5 μg/mL when necessary.
Molecular cloning
Molecular cloning techniques were performed according to Sambrook and Russell [30] . Preparation of competent cells and transformation Table 4 This work pNZnisA T6m1-3 CmR, nisA, T6 mutants Expression of hybrid peptide containing nisin(Δ30-34), with a 6-his tag and tails listed in Table 6 This work pNZnisA T6m4 CmR, T6 as hinge region between ABC rings and DE rings of nisin
Expression of hybrid peptide
This work were performed as described by Holo and Nes [31] . Restriction enzymes and ligase were supplied by Thermo-Fischer.
Construction of expression vectors
The peptidic tails were added to nisin genetically by round PCR. The primers ( Table 3) were designed to insert the tails between the nisin part and the restriction site HindIII. Each pair of primers contained a part annealing with the template vector pNZnisA leader his2 and a part encoding the peptide tail. After amplification, the PCR clean-up products were digested using DpnI to digest the template and ligated over-night. The ligation product was desalted and transformed into NZ9000, isolated, extracted and sequenced to verify the integrity of the sequence.
Protein expression
Each vector containing the mutant structural gene was transformed into NZ9000 (pIL3EryBTC). Cells were first cultured overnight in GM17 medium with 5 µg/mL chloramphenicol and 5 µg/mL erythromycin and transferred into MEM medium [3] at a final concentration of 2 %. 5 ng/mL nisin was added at the beginning of the inoculation and when the culture reached an OD (600 nm) of 0.4~0.6. Cells were harvested 3 h after the second induction by centrifugation for 20 min at 6500 rpm at 4 °C. The supernatant was kept for purification.
Strains or Plasmids
Characteristics Purpose References pNZnisA T8 m1-3 CmR, nisA, T8 mutants Expression of hybrid peptide containing nisin(Δ30-34), with a 6-his tag and tails listed in Table 6 This work pNZnisA T8m4 CmR, T8 as hinge region between ABC rings and DE rings of nisin
Expression of hybrid peptide
This work pNZnisA T16 m1-3 CmR, nisA, T16 mutants Expression of hybrid peptide containing nisin(Δ30-34), with a 6-his tag and tails listed in Table 6 This work pNZnisA T16m4 CmR, T16 as hinge region between ABC rings and DE rings of nisin
Expression of hybrid peptide This work
CmR: chloramphenicol resistance, EryR: erythromycin resistance.
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3 Table 3 . Primers for PCRs used in this study. Nucleotide Sequences  T1F  T1 Fwd  TCC ATA CCT TCC ACG TCC ACG TCC AGT TTA AGC TTT CTT TGA  ACC AAA ATT AG  T1F Rev  GTG GAA GGT ATG GAC GTG GTT TAT C TT TGC TTA CGT GAA  TAC TAC AAT G  T1S  T1S Rev  GTG GAA GGT ATG GAC GTG GTT TAT CAC CAC TAC AAT GAC  AAG TTG CTG  T2F  T2 Fwd  AAA TAC CTT CCA CGT CCA CGT CCA GTT TAA GCT TTC TTT  GAA CCA AAA TTA G  T2F Rev  CGT GGA CGT GGA AGG TAT TTA TC T TTG CTT ACG TGA ATA  CTA CAA TG  T2S T2S Rev TGG ACG TGG AAG GTA TTT ATC ACC ACT ACA ATG ACA AGT TGC T T3F T3 Fwd AAA ATC TCA ATC CAC CTT TAA GCT TTC TTT GAA CCA AAA TTA G T3F Rev TAA AGG TGG ATT GAG ATT TTG AAT GGT TTG CTT ACG TGA ATA CTA C T3S T3S Rev GGT GGA TTG AGA TTT TGA ATG GAC CAC TAC AAT GAC AAG TTG T4F T4 Fwd GCC ATG GTG GCC ATG GCG TCG TTA AGC TTT CTT TGA ACC AAA ATT AG T4F Rev GGC CAC CAT GGC CAT TTC CAT GGA AGG AT T TTG CTT ACG TGA ATA CTA CAA T T4S T4S Rev GGC CAC CAT GGC CAT TTC CAT GGA AGG ATA CCA CTA CAA TGA CAA GTT G  T5F  T5 Fwd  AAG GTA TCA AAA AAC TTT TCT AAG CTT TCT TTG AAC CAA AAT  TAG  T5F Rev TTG ATA CCT TTA AGG ATT TTA CCA AGG ATT TTG CTT ACG TGA  ATA CTA C  T5S  T5S Rev TTG ATA CCT TTA AGG ATT TTA CCA AGG ATA CCA CTA CAA TGA  CAA GTT G  T6F  T6 Fwd  GGT GTT CAA CCA AAA TAC TAA GCT TTC TTT GAA CC  T6F Rev ATT TTG GTT GAA CAC CGT TTT TGC TTA CGT GAA TAC TAC  T6S  T6S Rev ATT TTG GTT GAA CAC CGT TAC CAC TAC AAT GAC AAG TTG  T7F  T7 Fwd  TCA CTT CTT TCA GGT TGG GGT TAA GCT TTC TTT GAA CCA  AAA TTA G  T7F Rev CCA ACC TGA AAG AAG TGA ACC AGC GTT TTT GCT TAC GTG  AAT ACT AC  T7S  T7S Rev AAC CTG AAA GAA GTG AAC CAG CGT TAC CAC TAC AAT GAC  AAG TTG C  T8F  T8 Fwd  AAG TTG CTC TTA AAG CTC TTT AAG CTT TCT TTG AAC CAA  T8F Rev CTT TAA GAG CAA CTT TAG CGA TTT TTT TGC TTA CGT GAA TAC  TAC AAT G  T8S  T8S Rev CTT TAA GAG CAA CTT TAG CGA TTT TAC CAC TAC AAT GAC  AAG TTG  T9F  T9 Fwd  ACT TCT TTC AGG TCT TTC AGG TCT TCT TTA AGC TTT CTT TGA  ACC AAA ATT AG  T9F Rev GAA AGA CCT GAA AGA AGT TTA CCA GCG ATT GGA AGG AAT  TTG CTT ACG TGA ATA CTA C  T9S  T9S Rev GAA AGA CCT GAA AGA AGT TTA CCA GCG ATT GGA AGG AAA  CCA CTA CAA TGA CAA GTT G  T10F  T10 Fwd CAG GTC TTC TTG CTG GTC TTC TTT AAG CTT TCT TTG AAC CAA  AAT TAG  T10F Rev CAG CAA GAA GAC CTG GAA GGA ATT TGC TTA CGT GAA TAC  TAC AAT G  T10S T10S Rev CAG CAA GAA GAC CTG GAA GGA AAC CAC TAC AAT GAC AAG TTG Nucleotide Sequences  T11F  T11 Fwd TGG GTT TCT TCG GTG CTC GTT AAG CTT TCT TTG AAC CAA  AAT TAG  T11F Rev GCA CCG AAG AAA CCC ATA CCA GCA GCT TTG CTT ACG TGA  ATA CTA C  T11S  T11S Rev GCA CCG AAG AAA CCC ATA CCA GCA GCA CCA CTA CAA TGA  CAA GTT GC  T6m1  T6m1 Fwd AAC GGT GTT CAA CCA AAA TAC AAG TAA GCT TTC TTT GAA CC  T6S Rev  ATT TTG GTT GAA CAC CGT TAC CAC TAC AAT GAC AAG TTG  T6m2  T6m1 Fwd AAC GGT GTT CAA CCA AAA TAC AAG TAA GCT TTC TTT GAA CC  T6m2 Rev GTA TTT TGG TTG AAC ACC GTT TAC ACT ACA ATG ACA AGT  TGC TG  T6m3 T6F Fwd GGT GTT CAA CCA AAA TAC TAA GCT TTC TTT GAA CC T6m2 Rev GTA TTT TGG TTG AAC ACC GTT TAC ACT ACA ATG ACA AGT TGC TG T6m4
Mutants Primer
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Mutants Primer
T6m4 Fwd CGG TGT TCA ACC AAA ATA CAC AGC AAC TTG TCA TTG TAG T6m4 Rev GTA TTT TGG TTG AAC ACC GTT ACA ACC CAT CAG AGC TCC TG T8m1
T8m1 Fwd CGC TAA GGT TGC TCT TAA AGC TCT TAA GTA AGC TTT CTT TGA AC T8m1 Rev GAG CTT TAA GAG CAA CCT TAG CGA TTT TAC CAC TAC AAT GAC AAG TTG T8m2
T8m1 Fwd CGC TAA GGT TGC TCT TAA AGC TCT TAA GTA AGC TTT CTT TGA AC  T8m2 Rev GAG CTT TAA GAG CAA CCT TAG CGA TTT TTA CAC TAC AAT  GAC AAG TTG CTG TTT TC  T8m3  T8m3 Fwd CGC TAA GGT TGC TCT TAA AGC TCT TTA AGC TTT CTT TGA ACC  T8m2 Rev GAG CTT TAA GAG CAA CCT TAG CGA TTT TTA CAC TAC AAT  GAC AAG TTG CTG TTT TC  T8m4  T8m4 Fwd CGC TAA GGT TGC TCT TAA AGC TCT TAC AGC AAC TTG TCA  TTG TAG TAT TCA 
Protein purification, characterization and quantification
For fast detection of the designed peptides, a small volume of culture supernatant was used for precipitation using trichloroacetic acid (TCA) according to Sambrook and Russell [30] and the concentrated peptides were loaded on a 16 % Tricine SDS-PAGE gel [32] . Alternatively, for larger volume (≥1 L) cultures, the peptide was concentrated by cationic 89 3 exchange chromatography and gel filtration [33] . Samples were freezedried afterwards.
The freeze-dried sample was dissolved in 50 mM ammonium acetate, pH 6.0 for overnight digestion with purified NisP [27] . The active peptide was further purified by HPLC as indicated elsewhere [34] .
The fractions were collected, tested for activity against L. lactis and analyzed by MALDI-TOF MS [29] . The active and pure fraction was lyophilized and stored as powder until further use.
The quantification was performed by HPLC, as described previously [29] .
The synthetic peptides Tail T6m2, Tail T8m2 and Tail T16m2 were synthesized and provided with >99 % purity by Proteogenix (France).
Nisin was purified from commercial 2.5 % powder according to Slootweg et al. [35] .
Free-thiol alkylation
To investigate whether the fusions possess free cysteine residues, reactions with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) were performed. A linear peptide ADP (H-GIGKHVGKALK-GLKGLLKGLGEC-OH) was used as control. The reaction with CDAP was performed as described previously [36] . Mass spectra before and after reaction were recorded via MALDI-TOF MS [29] .
Determination of antimicrobial activity and minimal inhibitory concentration (MIC)
Antimicrobial activity was performed by well diffusion assay as described previously [29] . Minimal inhibitory concentration (MIC) tests were performed in triplicate by a liquid growth inhibition microdilution assays according to standard methods at 37 °C overnight [37] . Growth inhibition was assessed measuring OD (600 nm) using a microplate reader (Tecan infinite F200). The lowest concentration of the antimicrobials that inhibits detectable growth of the indicator strain is identified as the MIC.
Bactericidal activity assay
Gram-negative bacteria were incubated in 96-wells microplates at 37 °C overnight in the presence of nisin mutants at a final concentration of CHAPTER 3: Materials and methods 10 times the MIC. The number of bacterial cells was standardized at a final concentration of 5x105 cfu/mL. Two controls using fresh LB broth with or without bacterial inoculum were also performed in parallel in the same conditions. An aliquot was taken from each well and serially diluted in sterile PBS. Afterwards, 50 µL of each dilution was plated on LB agar plates. After overnight incubation at 37 ºC, bacterial colonies were enumerated to determine the amount of viable cells.
Results
Construction of peptide fusions containing a nisin part and
an anti-Gram-negative tail The first two rings of nisin can bind to lipid II to inhibit the cell wall synthesis and serve as a docking point for subsequent pore formation in the membrane [1] . However, due to its size, hydrophobicity and charge, nisin cannot efficiently pass through the outer-membrane of Gram-negative bacteria. Fusions containing both the nisin lipid II-binding part [38] and an outer membrane-penetrating part can kill Gram-negative pathogens more successfully than nisin alone due to the Trojan horse effect of the added tail [16] . Several new compounds were constructed in which the anti-Gram-negative tail was fused to either the ABC rings of nisin (data not shown), full nisin (Table 4, Group 1) or only ABCDE rings of nisin (Table 4 , Group 2). We found that the expression of fusions including rings ABC of nisin and the tails was less efficient than the structures in Group 1 and Group 2 constructs (data not shown), which was in agreement with previous reports [16] . So, we will only discuss the fusions with full nisin (Group 1) or five rings of nisin (Group 2) in this paper. In order to make the hybrid peptide shorter and more stable, the amino acid sequence "IHVSK" was deleted in Group 2 mutants. In this case an "SG" sequence was added to work as a flexible linker between the ABCDE rings of nisin and the tails ( Table 4 , Group 2). The sequences of the fusions are listed in Table 4 . The structures of these fusions are shown in Figure 1 
Characterization of fusions by MS and antimicrobial
activity All the fusions were induced and expressed with the nisin production system in L. lactis and then precipitated with TCA. Tricine SDS-PAGE was used to check the production level of the hybrid peptides. The mass of the peptides before leader peptide removal was determined via matrix-assisted laser desorption ionization-time of flight MALDI-TOF mass spectrometry (MS) to assess the modification extent of the hybrid peptides. Simultaneously, the antibiotic activity of the peptides activated using either in situ produced (L. lactis) or purified (E. coli) NisP [27] was tested for a qualitative antimicrobial screening. As Table 5 shows, the production level of some fusions was too low to show a clearly visible band in tricine SDS-PAGE, while some others were produced with high yields comparable to that of wild-type nisin produced using the same system ( Supplementary Figure 1) . The mass results indicated that the peptides T6F/S, T7F/S and T11F/S were not fully dehydrated. In all cases, a minimum of 5 dehydrations was detected. Considering the N-to C-directionality of NisBC, 5 dehydrations are enough to correctly construct rings ABC which preserve the lipid II binding capacity of nisin and retain partial antimicrobial activity [33, 38] . We observed that the mutant peptides T2F/S, T10F/S and T8F/S rendered a peptide with a mass smaller than the predicted mass. This might be due to degradation during the production or TCA precipitation. The nonspecific cleavage site in these peptides was not dependent on the sequence of the tail since the mass difference between the fusions to full nisin or rings ABCDE was not conserved (i.e. the full nisin and group 2 fusions were truncated differently). This phenomenon has been previously observed with fusions between nisin and anti-Gram-negative tails [16] . All of them exerted relatively high activity against L. lactis (pNZnisP8H) but only T2F, T6F, T8F and T8S showed activity against E. coli CECT101 (Figure 2) . This is probably observed because the first two rings of nisin can bind to lipid II while the last two rings can participate in pore formation leading to death of L. lactis [27, 38] . It could also be partly due to the sensitivity of L. lactis (pNZnisP8H), which was selected in the first screening for its reported increased sensitivity [27] . Thus, even poorly active or poorly produced compounds with activity against L. lactis NZ9000 (pNZni-sp8H) that would have been otherwise discarded during a screening against solely E.coli could be detected.
Designing mutants of tail 6, tail 8 and GNT16
Fusions containing tail 2, 6 and 8 showed good potential for further tests against Gram-negative pathogens. In addition, GNT 16 has been reported before to have relatively good outer membrane permeabilizing activity by our group [16] . Tail 2 (DKYLPRPRPV) and Tail 16 ( PRPPHPRL) were both proline rich peptides similarly to GNT16. So, tail 6, 8 and 16 were selected to be rationally modified and further studied, as shown in Table 6 . For TXm1 (X = tail 6, 8 or 16), a hydrophilic and positively charged lysine was added at the C-terminus of the peptides TXS (X = tail 6, 8 or 16), because many lantibiotics have a lysine at the C-terminus. In the mutants TXm2 (X = tail 6, 8 or 16), the glycine in the linker region between the nisin moiety and the tail in TXm1was substituted by valine, since valine can make this region a bit less flexible. TXm3 (X = tail 6, 8 or 16) mutants were composed of five rings of nisin and tails with "SV" in between. TXm4 (X = tail 6, 8 or 16) were designed in a totally different manner, using the anti-Gram-negative-peptide tail sequences as hinge region between rings ABC and rings DE of nisin, thus replacing the original NMK in the hinge region (Table 6 ).
Characterization of purified leaderless peptides
The active peptides were acquired by purification and digestion using purified NisP [27] to remove the leader part and activate the peptide. Their masses were measured by MALDI-TOF MS ( Supplementary  Figure 2 ) and the mass results are listed in Table 7 , which also shows the yields of the peptides. The results show that the peptides with tail 6 and 16 were not fully dehydrated, while peptides containing tail 8 were most likely degraded during the process of production or purification by exoproteases. T8m4, where the tail was placed as a hinge region and therefore not accessible to exoproteases, stayed as a full length peptide and no degradation was observed. The alkylation reaction with CDAP proved that there were no free thiol groups in the peptides (Supplementary Figure 3) . This fact, together with the activity, strongly suggests that the lanthionine rings possess the right regiochemistry.
Activity of the constructed fusions against Gram-negative pathogens
Activity tests of fusion mutants for T6, T8, and T16 were performed against five Gram-negative pathogens. The results of the MIC tests are provided in Table 8 . It is clear that nisin potency is reduced against these Gram-negative pathogens compared to the nanomolar activity that it displays against L. lactis. The MIC value of the designed peptides ranged CHAPTER 3: Results from 6 µM needed to inhibit A. baumannii to more than 48 µM against K. pneumoniae. Most of the mutants slightly outperformed nisin against some of the strains tested. Noteworthy, T6F improved the activity of nisin against five out of the six strains tested, including K. pneumoniae. After further design, TXm2 (X = tail 6, 8, or 16) had lower MIC values than TXm1, TXm3 and TXm4 did, especially T16m2. T16m2 displayed 4~12 times better activity than nisin against all the Gram-negative pathogens used, including E. aerogenes and K. pneumoniae, which were the most resistant bacteria against these compounds in the conditions tested. Of note, T16m2 was 12 times better than nisin against K. pneumoniae (β-lactamase producing strain) and A. baumannii. On the other hand, TXm4 (X = tail 6, 8, or 16) showed the worst activity against Gram-negative pathogens among the mutants. None of these peptides displayed improved activity, but rather displayed a drastic increase in the MIC value.
Unraveling the effect of the fusions on nisin activity
The added tails for the best three candidates T6m2, T8m2 and T16m2 were synthesized and tested for their activity against Gram-negative pathogens and the Gram-positive bacterium L. lactis MG1363. The MIC values are listed in Table 8 . None of the three tails alone showed activity against Gram-negative pathogens at the concentrations tested, with MIC values higher than 256 µM. Similarly, none of these three tail peptides could inhibit the growth of L. lactis at a concentration of 32 µM. These results indicate that the main role of the added tails was to assist the nisin part to pass through the outer-membrane, thus working as a carrier or gate-opener.
Next we investigated the effect of the added tails on the intrinsic killing mechanism of nisin. We used the Gram-positive species L. lactis as a model organism and confronted it with TXm2 and TXm4 mutants, where the tail behaves either as a C-terminal addition or as a hinge region, respectively. The MIC values of nisin and 6 fusions i.e. T6m2, T8m2, T16m2, T6m4, T8m4, and T16m4 are listed in Table 8 .
The MIC values of these 6 peptides were 62 times, 50 times, 42 times, 42 times, 33 times and 83 times, respectively, higher than the MIC of nisin. This clearly indicates that the tails have a negative influence on the intrinsic activity of nisin on the cytoplasmic membrane. 
Effect of EDTA on the activity of nisin against Gramnegative pathogens
As reported before [13] , when sufficient EDTA is added, a lower amount of nisin is needed to kill Gram-negative bacteria. In order to assess if the fusions change the spectrum of activity of nisin, we decided to compare the MIC of nisin in the presence of EDTA with that of the fusion peptides alone. In this work, different concentrations of EDTA were added together with nisin against Gram-negative pathogens. Untreated cells were used as a positive control. The results are listed in Table 9 . We could see that the pathogens displayed a different sensitivity to nisin when EDTA was used as an adjuvant. When 50 µM EDTA was added, the MIC value of nisin against E. coli and P. aeruginosa decreased 2 times while the MIC value against K. pneumoniae, A. baumannii and E. aerogenes did not change. At least 100 µM EDTA was needed to reduce the MIC value more than 2-fold, with K. pneumoniae being an exception. When comparing these MIC data ( Table 9 ) and that of nisin fusions alone (Table 8) , it was very obvious that the spectrum of activity of nisin was changed in the presence of either EDTA or the added tails.
Bactericidal effect of T16m2
The bactericidal effect of T16m2, the best candidate in our hands, was determined. Unlike the positive controls (untreated cells), no colonies of E. coli or A. baumannii could grow after the incubation with T16m2 (10-fold MIC) overnight ( Figure 3 ). There was no growth recovery after exposure to T16m2, so T16m2 was proven to be bactericidal.
Discussion
Antimicrobial resistance has become an imminent and ever-increasing global problem, which threatens public health and economic development. It has been reported that hospital infections caused by P. aeruginosa and A. baumannii are difficult to treat, since these pathogens are often resistant to most of the drugs clinically used [39] . What is more, E. aerogenes and K. pneumoniae strains resistant to the last generation of penicillins have already been isolated [39, 40] . There are pressing and urgent demands for the discovery of new antimicrobials to act against 99 3
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Gram-negative pathogens. Various authors indicate that antimicrobial peptides can constitute a suitable source of novel anti-Gram-negative compounds. In this work we investigate rationally designed nisin mutants for this purpose.
Nisin is the best studied lantibiotic, which exhibits high activity against Gram-positive bacteria, while its activity against Gramnegative microorganisms is drastically reduced. The outer-membrane of Gram-negative bacteria acts as a good protective barrier for nisin to pass through and thereby prevents nisin from reaching the innermembrane. In the presence of chelating agents or sublethal outermembrane perturbation, nisin can inhibit the growth of Gram-negative bacteria. However, the chelators or stress are not appropriate for most applications. In order to increase the ability of nisin to reach the inner membrane, we performed extensive engineering in this work. We chose a set of peptides that can naturally target Gram-negative bacteria and designed nisin fusions with tails that work as a Trojan horse. They were assayed against five clinically relevant (drug-resistant) Gram-negative species. We created functional fusions between nisin, which combines the pyrophosphate in lipid II (an underexploited drug target) to several peptides with capacity to cross the outer-membrane of Gram-negative bacteria.
The peptides with activity against Gram-negative bacteria were selected primarily on the basis of their capability of outer-membrane penetration and their inclusion in different structural groups (proline-rich, arginine-rich or cationic peptides). The preliminary screening and previous data focused our interest on the tails 6, 8 and 16 fused to the rings ABCDE of nisin. We confirmed that adding an anti-Gram negative tail to either nisin or a truncated version of nisin is an efficient way to improve its activity against Gram-negative pathogens. However, the addition of an extra stretch of amino acids can make it prone to partial proteolytic degradation as we could observe for the mutants T2, T8 and T10 (Table 5 ). These mutants rendered one major product with a reduced mass but still retaining activity.
The set of mutants where the anti-Gram-negative tail replaces nisin's hinge region, TXm4 (X = tail 6, 8, or 16), failed against Gram-negative pathogens in this study. However, they still retained activity against L. lactis MG1363 (Table 8 ). Thus, the outer-membrane penetrating capacity in TXm4 mutants is, in the best case, minimal, which indicates that the tails used in our study could optimally perform the expected activity when they were used as C-terminal extensions of nisin. Moreover, the results confirmed that changes in the hinge region will affect the structure and activity of the entire peptide [34] . The location of the tail in the hinge region in TXm4 decreased its outer-membrane traversing capacity and therefore that of the whole fusion peptide. Our results clearly discourage the use of the selected tails as a replacement of the nisin hinge region for antimicrobial activity improvement.
Variations in the region linking ring E of nisin to the peptide with activity against Gram-negative bacteria (the Gly to Val mutation in T8m3 and T16m3) exerted better activity against specific pathogens than T8S and T16S, respectively. T8m3 was 2 times better than T8S 3 against K. pneumoniae while T16m3 was more than 4 times better. T16m3 was remarkably more active than GNT16SG against E. coli (MICs, 8 µM and >32 µM, respectively), K. pneumoniae (MICs, 16 µM and >64 µM, respectively), A. baumannii (MICs, 1µM and 8uM, respectively) and E. aerogenes (MICs, 16 µM and >32 µM, respectively). These results establish that replacing glycine by valine in the linker region significantly enhances the activity of these peptides against the tested Gram-negative pathogens.
Since most lantibiotics described previously in literature contain either a positively charged amino acid at the C-terminus or have undergone specific enzymatic C-terminal decarboxylation, a set of mutants with an extra lysine was created to mimic that situation. T8m2 is 2~6 times better than nisin against selected pathogenic strains. The activity of T16m2 against P. aeruginosa, E. coli and E. aerogenes was enhanced 4.5 times, 6 times, and 8 times, respectively. Most notably, the MIC value of T16m2 against K. pneumoniae and A.baumannii was 12 times lower when compared to that of nisin.
T16m1, 2, and 3 shared the same anti-Gram negative tail with GNT16 and GNT16SG, but T16m2 rendered the best results followed by T8m2. The MIC value difference of T16m2 compared to GNT16SG against E. coli and K. pneumoniae was more than 16-fold. It indicates the importance of a C-terminal lysine as well as valine in the flexible linker region connecting nisin and the tail. The reason might be that the lysine residue at the C-terminus has a better interaction with the negatively charged phospholipids to facilitate translocation, while valine in the linker region might facilitate interaction with the membrane lipophilic part. However, the effect of the mutation Gly to Val was detrimental for the activity of T16m3. This effect was counteracted when lysine was added in T16m2, which outperforms the mutant T16m1, where glycine was present. Collectively, our results show that the simultaneous mutation of glycine to valine and the insertion of a C-terminal lysine improves the antimicrobial activity of all the constructs.
T6m2 ,T8m2 and T16m2 were proven to be the best candidates in their specific similar tails sets. As shown in Table 8 , the low activity of the tails alone of T6m2, T8m2 and T16m2 against Gram-negative pathogens (MIC value >256 µM) and the Gram-positive bacterium CHAPTER 3: Discussion L. lactis MG1363 (MIC value >32 µM), illustrates the role of the tails as mainly trans-membrane carriers rather than being bactericidal themselves. The nisin-tail fusions were more than 50 times less potent against L. lactis MG1363 than nisin. Thus, the activity of the nisin part on the inner-membrane was extremely compromised by adding tails. After treatment with different concentrations of EDTA, a lower amount of nisin was needed to kill the Gram-negative pathogens. However, the spectrum of activity of nisin fusions against Gram-negative pathogens was different from that of nisin against Gram-negative pathogens that had been treated with EDTA. T16m2 was shown to be 6 times, 12 times, 4.5 times, 12 times and 8 times better than nisin against E. coli, K. neumoniae, P. aeruginosa, A. baumannii and E. aerogenes, respectively. For comparison, the pathogens treated with 200 µM EDTA, were 4 times, 2 times, 16 times, 4 times and 4 times more sensitive to nisin ( Table 9 ). We also showed that T16m2 exerts a bactericidal effect against E. coli and A. baumannii (Figure 3 ). In conclusion, the tails of the fusions changed both the activity and spectrum of activity of nisin, but the fusion was still bactericidal.
Previous work [16] showed that the activity of the model lantibiotic nisin can be improved 2-fold against E. coli by the combination of functional domains of different antimicrobial peptides, namely apidaecin and nisin. Our data show that by rational design it was possible to further improve the activity of nisin up to 12-fold against selected pathogenic (drug-resistant) Gram-negative bacteria either in health. These data provide new design principles for further engineering that can lead to the development of highly potent lantibiotic-derivatives specifically targeting Gram-negative bacteria. Applications could range from food protection to clinical applications. For the latter, further preclinical studies on toxicity, stability and PK/PD would be required.
